BioViva Sciences Inc is a pioneering biotechnology company focused on improving human longevity through gene therapy. As cells age, their ability to function and repair damage diminishes, leading to serious health issues. Unlike traditional medicine that treats symptoms, BioViva's personalized regenerative gene therapies target the root cause of cellular aging.

The company holds patents for innovative gene delivery processes, including adeno-associated virus (AAV) and CMV, which allow therapeutic genes to be delivered into human cells more effectively. Animal studies have shown that CMV treatment can extend lifespan by over 41%. Additionally, CMV is being used in immunotherapies for cancer, AIDS, and malaria.

By extending health spans instead of just lifespans, BioViva aims to address the growing elderly population's susceptibility to aging-associated diseases and COVID-19. The company's gene therapy has the potential to halt diseases and offer cures for currently incurable conditions. Led by CEO Liz Parrish, who has undergone gene therapy herself, BioViva is dedicated to finding solutions to aging-related decline and reducing the impact of disease.

With ongoing research and expanding gene candidates, BioViva remains at the forefront of gene therapy innovation